Provided by Tiger Trade Technology Pte. Ltd.

Park Hotels & Resorts Inc.

10.60
+0.19001.83%
Pre-market: 10.700.1000+0.94%08:00 EDT
Volume:3.07M
Turnover:32.54M
Market Cap:2.13B
PE:-7.41
High:10.68
Open:10.54
Low:10.46
Close:10.41
52wk High:12.39
52wk Low:8.27
Shares:201.40M
Float Shares:195.63M
Volume Ratio:0.93
T/O Rate:1.57%
Dividend:1.00
Dividend Rate:9.43%
EPS(TTM):-1.4300
EPS(LYR):-1.4300
ROE:-8.31%
ROA:2.12%
PB:0.68
PE(LYR):-7.41

Loading ...

Ascentage Pharma Announces IND Clearance by the U.S. Food and Drug Administration for BTK Degrader APG-3288

GlobeNewswire
·
Jan 07

Park Hotels & Resorts Initiated at Overweight by Barclays

Dow Jones
·
Jan 06

NovaBridge Presents Positive Givastomig Dose Expansion Data from the Phase 1b Combination Study in Patients with 1L Metastatic Gastric Cancer

GlobeNewswire
·
Jan 06

Aclaris Therapeutics Announces Positive Interim Results of Phase 1a Trial of Anti-TSLP/IL-4Rα Bispecific Antibody ATI-052 Supporting Expedited Clinical Development

GlobeNewswire
·
Jan 06

Crescent Biopharma Announces Regulatory Clearances of IND Applications for CR-001, a PD-1 x VEGF Bispecific Antibody and CR-003, an ITGB6-targeted ADC, for the Treatment of Solid Tumors

GlobeNewswire
·
Jan 05

Three Partners Launch Independent Law Practice Following Departure from Mayer Brown PK Wong & Nair

prnewswire
·
Jan 02

U.S. FDA Approves Agios’ AQVESME™ (mitapivat) for the Treatment of Anemia in Adults with Alpha- or Beta-Thalassemia

GlobeNewswire
·
Dec 24, 2025

Assessing Park Hotels & Resorts (PK) Valuation After Recent Share Price Underperformance

Simply Wall St.
·
Dec 23, 2025

SAB BIO Announces Positive Confirmatory Clinical Results from the Phase 1 Study of SAB-142 in Development for the Treatment of Stage 3 T1D

GlobeNewswire
·
Dec 17, 2025

GRI Bio Announces Positive Topline Data from its Phase 2a Study in Idiopathic Pulmonary Fibrosis (“IPF”)

GlobeNewswire
·
Dec 11, 2025

Park Hotels & Resorts to Sell Three More Non-Core Properties, Reaffirms 2025 Outlook

MT Newswires Live
·
Dec 09, 2025

BRIEF-Park Hotels & Resorts Announces The Sale Of Additional Non-Core Hotels

Reuters
·
Dec 09, 2025

Park Hotels & Resorts Sells Five Non-Core Hotels for $198 Million

Reuters
·
Dec 09, 2025

Park Hotels & Resorts Inc: Reaffirms FY 2025 Outlook With Oct and Prelim Nov Comparable Revpar Results Largely in Line With Expectations

THOMSON REUTERS
·
Dec 09, 2025

Park Hotels & Resorts Announces the Sale of Additional Non-Core Hotels and Provides Update on Non-Core Hotel Disposition Activity and Recent Operating Trends

THOMSON REUTERS
·
Dec 09, 2025

Three Leading Jiangsu City Commercial Banks Compared: Bank of Jiangsu Leads in Profit, Bank of Nanjing in Revenue Growth, Bank of Suzhou in Risk Control

Deep News
·
Dec 05, 2025

Last Patient Completes Biofrontera’s Phase 1 Pharmacokinetics Study of Ameluz® for Treatment of Actinic Keratoses on the Trunk and Extremities

GlobeNewswire
·
Dec 04, 2025

Absci Announces First Participants Dosed in Phase 1/2a HEADLINE™ Trial of AI-Designed Antibody ABS-201™ for Androgenetic Alopecia

GlobeNewswire
·
Dec 04, 2025

Truist Raises Price Target on Park Hotels & Resorts to $12 From $11, Keeps Hold Rating

MT Newswires Live
·
Dec 04, 2025

Press Release: Pasithea Therapeutics Announces Closing of $60 Million Public Offering of Common Stock

Dow Jones
·
Dec 02, 2025